The 28-day mortality rate was similar between groups, and 22% of patients in the albumin group discontinued the treatment due to adverse effects (primarily pulmonary edema or bronchospasm) compared to no patients in the PlasmaLyte group. Here, ALB is linked to pulmonary edema.